ABOUT THIS STUDY
- Enrolled in the Corrona RA Registry and initiated tofacitinib on or after November 2012
- Initiate tofacitinib (defined as first ever use of tofacitinib) at the Corrona enrollment visit or at a Corrona follow-up visit from November 2012 onward.
- Have CDAI measured at baseline
- Have at least a 6-month follow-up visit and CDAI measured at the 6-month follow-up visit
- There are no exclusion criteria for this study
TRY A NEW SEARCH
Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Based on your search, you may also be interested in
- New York, New York
- Birmingham, Alabama